Position in AZN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$933,499
-$37,415 QoQ
Shares Held
4,923
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.29%
of 13F equity value
Holder Rank
#684
of 1,459 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AZN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Calydon Capital holds $35,751,780 across 10 Drug Manufacturers - General names. AZN ranks #6 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
36,979 | $9,391,556 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
58,233 | $7,357,157 | |
| 3 | AMGN |
Amgen Inc
|
20,308 | $7,353,932 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
123,497 | $7,115,897 | |
| 5 | LLY |
ELI LILLY & Co
|
1,509 | $1,809,940 | |
| 6 | AZN |
Astrazeneca PLC
This page
|
4,923 | $933,499 | |
| 7 | NVS |
Novartis AG
|
5,755 | $901,923 | |
| 8 | MRK |
Merck & Co., Inc.
|
2,772 | $356,202 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $933,499 | 4,923 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $970,914 | 4,923 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $905,326 | 9,848 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||